Medical expert of the article
New publications
Preparations
Orzid
Last reviewed: 03.07.2025
All iLive content is medically reviewed or fact checked to ensure as much factual accuracy as possible.
We have strict sourcing guidelines and only link to reputable media sites, academic research institutions and, whenever possible, medically peer reviewed studies. Note that the numbers in parentheses ([1], [2], etc.) are clickable links to these studies.
If you feel that any of our content is inaccurate, out-of-date, or otherwise questionable, please select it and press Ctrl + Enter.
Orzid is an antibiotic from the 3rd generation cephalosporin subgroup. Its active component is ceftazidime, which has a bactericidal effect by slowing down the activity of microbial cell membranes.
It exhibits a broad spectrum of antibacterial activity against Gram-negative and -positive bacteria, as well as anaerobes and aerobes. Acquired antibiotic resistance varies from region to region and may change over time, differing significantly for some strains. Local antibiotic susceptibility information should be consulted, particularly when treating severe infections.
[ 1 ]
Indications Orzida
It is used in cases of diseases caused by the action of microbes sensitive to the drug. Among them are lesions of the gastrointestinal tract, joints with bones and soft tissues, respiratory and urogenital systems, peritoneum and nervous system. In addition, it is used in sepsis and in case of complications after operations (and to prevent them).
Release form
The medicinal substance is released in the form of a lyophilisate for infusion fluid, inside vials with a capacity of 0.25, 0.5 and 1 g.
Pharmacokinetics
The administered ceftazidime can penetrate into all fluids with tissues, reaching medicinal values there. Distribution also occurs inside the gallbladder, myocardium, bones with soft tissues and epidermis. The substance overcomes the intact BBB poorly, but in case of inflammation of the meninges, its level inside the cerebrospinal fluid acquires therapeutic value, which is sufficient for the treatment of meningitis.
High levels of the drug remain in the body for 8-12 hours. The half-life in case of stable kidney function is 1.8 hours, and in case of impaired kidney function – 2.2 hours.
Ceftazidime is not subject to intrahepatic metabolic processes, which is why people with liver problems do not need to reduce the dose of the drug.
Orzid is excreted through the kidneys unchanged (80-90%).
The dosage of the drug for people with renal impairment should be significantly lower than the standard.
Dosing and administration
Orzid is used exclusively parenterally (intramuscular or intravenous injections). Portions are selected individually, taking into account the patient's weight and age, the sensitivity of the causative bacteria, the nature of the disease and the state of renal function.
Adults are usually administered 1 g of the drug 3 times a day or 2 g at 12-hour intervals.
In cases of severe forms of infection or for people with weakened immunity, the dosage of the medication is 2 g, administered at 8-hour intervals.
For damage to joints and bones, 2000 mg of the medicine is used twice a day.
Infants under 2 months of age are given 25-50 mg/kg in 2 injections. Children older than this age require 30-100 mg/kg (in 2-3 injections) per day.
Children with weakened immunity, as well as with meningitis or cystic fibrosis, require a dosage of up to 0.15 g/kg per day (no more than 6 g per day) in 3 injections.
Elderly people are allowed to take no more than 3000 mg of the drug per day.
People with renal insufficiency should initially use 1 g of the drug. The maintenance dose is selected taking into account the CC rate.
Methods of diluting medicinal products.
When performing intramuscular procedures, the lyophilisate is diluted in injection fluid or isotonic NaCl (2-3 ml).
For intravenous jet injections, the medication must be diluted in 10 ml of the selected solvent.
In case of intravenous administration through a dropper, the medicine is diluted in 50 ml of a solvent.
Solutions containing ceftazidime have physical and chemical stability for 7 days (temperature 4 o C) or 18 hours (room temperature).
Use Orzida during pregnancy
Ceftazidime crosses the placenta, which is why it cannot be used in the 1st trimester. In the 2nd and 3rd trimesters, it is used only in situations where the benefit from the administration of the drug is more likely than the risks of complications.
Because the drug is excreted in breast milk, it should be used with great caution during breastfeeding.
Side effects Orzida
Main side effects:
- allergy symptoms: eosinophilia, Quincke's edema, fever, TEN, epidermal itching, urticaria, bronchospasm, erythema multiforme (this includes SSc) and anaphylaxis;
- local manifestations: after an intravenous injection, phlebitis develops; after an intramuscular injection, a hardening, pain, abscess and burning sensation occur at the injection site;
- disorders of the nervous system: paresthesia, encephalopathy, headaches, fluttering tremors, generalized seizures and dizziness;
- problems with the function of the urogenital system: candidal vaginitis, kidney dysfunction and toxic nephropathy;
- lesions affecting the gastrointestinal tract: intestinal disorder, vomiting, pain in the epigastric region, nausea, cholestasis and colitis;
- disorders associated with the blood system: leuko-, thrombocyto- or neutropenia, lymphocytosis, hemolytic anemia and hemorrhages.
Overdose
After the administration of an excessively large dose of Orzid, the following symptoms may occur: vomiting, convulsions, acute renal failure, nausea, coma and dizziness.
The drug has no antidote. In case of intoxication, symptomatic measures are taken to stabilize and support the functioning of vital body systems. In case of severe poisoning, the drug level can be reduced by performing a hemodialysis procedure.
Interactions with other drugs
The administration of the drug together with other nephrotoxic agents, including diuretics (furosemide), or aminoglycosides can cause renal failure (especially in individuals with disorders of this function).
The combination of ceftazidime with chloramphenicol weakens the therapeutic effect of both drugs.
Ceftazidime is not compatible with sodium hydrochloride solution, and therefore it is prohibited to use it for diluting drugs.
When taking Orzid, you should not drink alcohol.
Shelf life
Orzid can be used within a 3-year period from the date of manufacture of the therapeutic product. The shelf life of the injection liquid is 5 years.
[ 18 ]
Analogues
The analogs of the drug are the substances Vicef and Fortum with Ceftazidime.
Attention!
To simplify the perception of information, this instruction for use of the drug "Orzid" translated and presented in a special form on the basis of the official instructions for medical use of the drug. Before use read the annotation that came directly to medicines.
Description provided for informational purposes and is not a guide to self-healing. The need for this drug, the purpose of the treatment regimen, methods and dose of the drug is determined solely by the attending physician. Self-medication is dangerous for your health.